Akero Therapeutics, Inc. AKRO
Set alert
54.65 USD 0.00 0.00%
At close · Dec 9
54.69 +0.04 +0.07%
After hours · Dec 9, 4:00 PM ET
54.52 Day range 54.65
53.84 52-week range 54.83
- YTD
- +96.44%
- 1 year
- +75.67%
- Open
- 54.52
- Prev close
- 54.65
- Mkt cap
- 4.50B
- Vol
- 11.61M
- Avg vol
- 2.29M
- EPS
- -1.94
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 54.52
- High
- 54.65
- Beta
- -0.40
- Inst. own
- 112.47%
- Dividend
- 0.00
Analyst view
Price target (mean) —
Ratings (0m) 12 12 buy · 0 hold · 0 sell
- Strong buy9
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.9333 | -1.00 – -0.89 | -1.05 | +11.1% | 0 | 0.0% | 6 |
| Current quarter | -0.9002 | -1.07 – -0.5855 | -0.81 | -11.1% | 0 | 0.0% | 7 |
| Current quarter | -0.9917 | -1.09 – -0.94 | -0.90 | -10.2% | 0 | 0.0% | 5 |
| Current quarter | -0.90 | -1.01 – -0.84 | -0.71 | -26.8% | 0 | 0.0% | 6 |
| Current quarter | -0.90 | -1.15 – -0.64 | -0.60 | -50.0% | 0 | 0.0% | 8 |
| Current quarter | -0.95 | -1.15 – -0.64 | -0.55 | -72.7% | 0 | 0.0% | 7 |
| Current quarter | -0.68 | -0.72 – -0.61 | -0.92 | +26.1% | 0 | 0.0% | 8 |
| Current quarter | -0.63 | -0.68 – -0.58 | -0.77 | +18.2% | 0 | 0.0% | 5 |
| Current quarter | -0.67 | -0.80 – -0.58 | -0.74 | +9.5% | 0 | 0.0% | 5 |
| Current quarter | -0.74 | -0.81 – -0.64 | -0.70 | -5.7% | 0 | 0.0% | 5 |
| Current quarter | -0.86 | -1.04 – -0.72 | -0.83 | -3.6% | 0 | 0.0% | 5 |
| Current quarter | -0.80 | -0.96 – -0.72 | -0.43 | -86.0% | 0 | 0.0% | 5 |
| Current quarter | -0.92 | -1.15 – -0.83 | -0.63 | -46.0% | 0 | 0.0% | 6 |
| Current quarter | -0.72 | -1.03 – -0.51 | -0.57 | -26.3% | 0 | 0.0% | 6 |
| Current quarter | -0.91 | -1.28 – -0.74 | -0.42 | -116.7% | 0 | 0.0% | 7 |
| Current quarter | -0.65 | -1.42 – -0.39 | -0.56 | -16.1% | 0 | 0.0% | 6 |
| Current quarter | -0.62 | -1.03 – -0.42 | -2.21 | +71.9% | 0 | 0.0% | 5 |
| Current quarter | -0.61 | -0.63 – -0.59 | 0.00 | 0.0% | 0 | 0.0% | 5 |
| Current quarter | -0.43 | -0.45 – -0.40 | 0.00 | 0.0% | 0 | 0.0% | 3 |
| Current quarter | -0.36 | -0.45 – -0.29 | 0.00 | 0.0% | 0 | 0.0% | 3 |
| Next quarter | -1.01 | -1.12 – -0.95 | -0.90 | -12.2% | 0 | 0.0% | 3 |
| Current year | -3.94 | -4.23 – -3.65 | -3.75 | -4.9% | 0 | 0.0% | 4 |
| Current year | -3.95 | -4.27 – -3.84 | -2.89 | -36.7% | 0 | 0.0% | 10 |
| Current year | -2.84 | -3.12 – -2.66 | -2.87 | +1.0% | 0 | 0.0% | 8 |
| Current year | -3.21 | -3.33 – -3.06 | -2.89 | -11.1% | 0 | 0.0% | 6 |
| Current year | -2.77 | -2.84 – -2.66 | -2.52 | -9.9% | 0 | 0.0% | 6 |
| Current year | -2.21 | -2.29 – -2.11 | -2.90 | +23.8% | 0 | 0.0% | 7 |
| Current year | -2.81 | -3.50 – -1.89 | 0.00 | 0.0% | 0 | 0.0% | 6 |
| Next year | -4.22 | -4.58 – -3.98 | -3.94 | -7.3% | 0 | 0.0% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 10, 2025 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Oct 10, 2025 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Oct 9, 2025 | Jefferies | Downgrade | Buy | Hold |
| Oct 9, 2025 | Canaccord Genuity | Downgrade | Buy | Hold |
| Aug 4, 2025 | TD Cowen | Initiated | — | Buy |
| May 27, 2025 | B of A Securities | Maintained | Buy | Buy |
| May 13, 2025 | Citigroup | Maintained | Buy | Buy |
| Mar 3, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 31, 2025 | UBS | Maintained | Buy | Buy |
| Jan 30, 2025 | B of A Securities | Upgrade | Neutral | Buy |
| Jan 27, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 16, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 18, 2024 | Citigroup | Initiated | — | Buy |
| Nov 18, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 11, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 20, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Jun 12, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Jun 11, 2024 | Wolfe Research | Initiated | — | Outperform |
| Jun 11, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 15, 2024 | Evercore ISI Group | Maintained | Outperform | Outperform |
| May 13, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 5, 2024 | UBS | Maintained | Buy | Buy |
| Mar 5, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 1, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 14, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 12, 2023 | UBS | Maintained | Buy | Buy |
| Oct 11, 2023 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 11, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |